Summary
Shares of Zydus Lifesciences dropped over two percent after reporting a 36% year-on-year profit decline for Q1, despite a nearly 22% increase in operational revenue and a 41% surge in expenses. Nuvama analysts, however, upgraded the stock to 'Buy' with a higher price target.